PROM1 and cancer: Vives et al. reported that metronomic cyclophosphamide could reduce the number of CD133+ precursor cells and triple-positive CD133+/CD44+/CD24+ cancer stem cells in orthotopic models of human pancreatic adenocarcinoma 72 (Figure 1).